Thrombelastography-Directed Transfusion in Cardiac Surgery: Impact on Postoperative Outcomes.


Journal

The Annals of thoracic surgery
ISSN: 1552-6259
Titre abrégé: Ann Thorac Surg
Pays: Netherlands
ID NLM: 15030100R

Informations de publication

Date de publication:
May 2019
Historique:
received: 23 03 2018
revised: 11 12 2018
accepted: 07 01 2019
pubmed: 16 2 2019
medline: 19 12 2019
entrez: 16 2 2019
Statut: ppublish

Résumé

Transfusion of allogenic blood products is associated with substantial morbidity and increased risk of mortality. Thrombelastography (TEG) to direct transfusion management during and immediately after cardiothoracic surgery reduced blood product usage in our institution. The goal of this study was to quantify the impact of TEG on postoperative outcomes. All patients who underwent cardiac surgical procedures before and after implementation of TEG were retrospectively analyzed. Baseline patient characteristics, blood product administration, and length of stay (LOS) were compared. A logistic regression model was used to evaluate the impact of TEG on the odds of reoperation, LOS, and 6-month mortality. Included in analysis were 367 patients in the pre-TEG period and 310 patients in the post-TEG period. Baseline characteristics did not vary between periods. Exposure to blood products was significantly reduced after implementation of TEG (p < 0.001). The incidence of reoperation was lower in the post-TEG period (7.1% versus 3.5%, p = 0.04). Controlling for related factors on multivariate analysis, TEG was associated with reduction in postoperative LOS (11.3 versus 9.9 days, p = 0.04) and 6-month mortality (odds ratio 2.98, 95% confidence limits: 1.13 and 7.85). The use of TEG to guide blood product administration substantially affected patient outcomes, including LOS, odds of reoperation, and short-term mortality. The impacts appreciated may be due to the reduced use of allogenic blood products and the ability to distinguish between postoperative coagulopathy and surgical bleeding with the use of this point-of-care test.

Sections du résumé

BACKGROUND BACKGROUND
Transfusion of allogenic blood products is associated with substantial morbidity and increased risk of mortality. Thrombelastography (TEG) to direct transfusion management during and immediately after cardiothoracic surgery reduced blood product usage in our institution. The goal of this study was to quantify the impact of TEG on postoperative outcomes.
METHODS METHODS
All patients who underwent cardiac surgical procedures before and after implementation of TEG were retrospectively analyzed. Baseline patient characteristics, blood product administration, and length of stay (LOS) were compared. A logistic regression model was used to evaluate the impact of TEG on the odds of reoperation, LOS, and 6-month mortality.
RESULTS RESULTS
Included in analysis were 367 patients in the pre-TEG period and 310 patients in the post-TEG period. Baseline characteristics did not vary between periods. Exposure to blood products was significantly reduced after implementation of TEG (p < 0.001). The incidence of reoperation was lower in the post-TEG period (7.1% versus 3.5%, p = 0.04). Controlling for related factors on multivariate analysis, TEG was associated with reduction in postoperative LOS (11.3 versus 9.9 days, p = 0.04) and 6-month mortality (odds ratio 2.98, 95% confidence limits: 1.13 and 7.85).
CONCLUSIONS CONCLUSIONS
The use of TEG to guide blood product administration substantially affected patient outcomes, including LOS, odds of reoperation, and short-term mortality. The impacts appreciated may be due to the reduced use of allogenic blood products and the ability to distinguish between postoperative coagulopathy and surgical bleeding with the use of this point-of-care test.

Identifiants

pubmed: 30768933
pii: S0003-4975(19)30195-X
doi: 10.1016/j.athoracsur.2019.01.018
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1313-1318

Informations de copyright

Copyright © 2019 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Auteurs

Roberta E Redfern (RE)

Research Department, ProMedica Toledo Hospital, Toledo, Ohio.

Kevin Fleming (K)

Department of Perfusion Services, ProMedica Toledo Hospital, Toledo, Ohio.

Rebekah L March (RL)

Department of Public Health and Preventive Medicine, University of Toledo, Toledo, Ohio.

Nathan Bobulski (N)

Department of Perfusion Services, ProMedica Toledo Hospital, Toledo, Ohio.

Michael Kuehne (M)

Department of Cardiothoracic Surgery, ProMedica Toledo Hospital, Toledo, Ohio.

John T Chen (JT)

Department of Statistics and Mathematics, Bowling Green State University, Bowling Green, Ohio.

Michael Moront (M)

Department of Cardiothoracic Surgery, ProMedica Toledo Hospital, Toledo, Ohio. Electronic address: morontmd@icloud.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH